# The Influence of the Auxiliary Ligand in Monofunctional Pt(II) Anticancer Complexes on the DNA Backbone

**Authors:** Evanthia-Vasiliki Tagari, Evangelia Sifnaiou, Theodoros Tsolis, Achilleas Garoufis

PMC · DOI: 10.3390/ijms25126526 · 2024-06-13

## TL;DR

This study explores how different auxiliary ligands in platinum-based anticancer complexes affect their DNA interactions and cancer cell toxicity.

## Contribution

The paper reveals how ligand bulkiness and aromaticity influence DNA binding and cytotoxicity in monofunctional Pt(II) complexes.

## Key findings

- Complexes with bulkier ligands showed slower hydrolysis rates and distinct DNA binding behaviors.
- Only the complex with a phenyl-substituted pyridine ligand exhibited significant cytotoxicity against A549 lung cancer cells.
- Steric hindrance from ligand substituents altered sugar conformation dynamics in DNA model compounds.

## Abstract

Monofunctional platinum complexes offer a promising alternative to cisplatin in cancer chemotherapy, showing a unique mechanism of action. Their ability to induce minor helix distortions effectively inhibits DNA transcription. In our study, we synthesized and characterized three monofunctional Pt(II) complexes with the general formula [Pt(en)(L)Cl]NO3, where en = ethylenediamine, and L = pyridine (py), 2-methylpyridine (2-mepy), and 2-phenylpyridine (2-phpy). The hydrolysis rates of [Pt(en)(py)Cl]NO3 (1) and [Pt(en)(2-mepy)Cl]NO3 (2) decrease with the bulkiness of the auxiliary ligand with k(1) = 2.28 ± 0.15 × 10−4 s−1 and k(2) = 8.69 ± 0.98 × 10−5 s−1 at 298 K. The complex [Pt(en)(2-phpy)Cl]Cl (3) demonstrated distinct behavior. Upon hydrolysis, an equilibrium (Keq = 0.385 mM) between the complexes [Pt(en)(2-phpy)Cl]+ and [Pt(en)(2-phpy-H+)]+ was observed with no evidence (NMR or HR-ESI-MS) for the presence of the aquated complex [Pt(en)(2-phpy)(H2O)]2+. Despite the kinetic similarities between phenanthriplatin and (2), complexes (1) and (2) exhibit minimal activity against A549 lung cancer cell line (IC50 > 100 μΜ), whereas complex (3) exhibits notable cytotoxicity (IC50 = 41.11 ± 2.1 μΜ). In examining the DNA binding of (1) and (2) to the DNA model guanosine (guo), we validated their binding through guoN7, which led to an increased population of the C3′-endo sugar conformation, as expected. However, we observed that the rapid transition 2E (C2′-endo) ↔ 3E (C3′-endo), in the case of [Pt(en)(py)(guo)](NO3)2 ([1-guo]), slows down in the case of [Pt(en)(2-mepy)(guo)](NO3)2 ([2-guo]), resulting in separate signals for the two conformers in the 1H NMR spectra. This phenomenon arises from the steric hindrance between the methyl group of pyridine and the sugar moiety of guanosine. Notably, this hindrance is absent in [2-(9-MeG)] (9-MeG = 9-methylguanine), probably due to the absence of a bulky sugar unit in 9-MeG. In the case of (3), where the bulkiness of the substitution on the pyridine is further increased by a phenyl group, we observed a notable proximity between 9-MeGH8 and the phenyl ring of 2-phpy. Considering that only (3) exhibited good cytotoxicity against the A549 cancer cell line, it is suggested that auxiliary ligands, L, with an extended aromatic system and proper orientation in complexes of the type cis-[Pt(en)(L)Cl]NO3, may enhance the cytotoxic activity of such complexes.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033), ethylenediamine (PubChem CID 3301), pyridine (PubChem CID 1049), 2-methylpyridine (PubChem CID 7975), 2-phenylpyridine (PubChem CID 13887), guanosine (PubChem CID 135398635), 9-methylguanine (PubChem CID 135403591)
- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), lung cancer (MESH:D008175), cytotoxic (MESH:D064420)
- **Chemicals:** sugar (MESH:D000073893), guanosine (MESH:D006151), ethylenediamine (MESH:C031234), phenanthriplatin (MESH:C587603), 2-mepy (MESH:C530793), 9-MeG (MESH:C116701), [2-(9-MeG)] (-), cisplatin (MESH:D002945), py (MESH:C023666), 2-phenylpyridine (MESH:C058324), L (MESH:D007930)
- **Cell lines:** A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), A549 cancer — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_E025)

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11203703/full.md

---
Source: https://tomesphere.com/paper/PMC11203703